Ashley L. Pappas, PharmD, BCPS

Entyvio, manufactured by Takeda Pharmaceuticals, was approved in May 2014 for the treatment of adult patients with moderate to severe ulcerative colitis or Crohn's disease.

Keytruda, manufactured by Merck, is indicated for treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor.

Cyramza, manufactured by Eli Lilly and Company, is an angiogenesis inhibitor indicated for the treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after treatment with prior fluoropyrimidine- or platinum-containing chemotherapy.

Gazyva is a novel anti-CD20 monoclonal antibody approved, in combination with chlorambucil, for the treatment of previously untreated chronic lymphocytic leukemia patients.

Tbo-filgrastim (Granix) is FDA approved to reduce the duration of severe neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy with significant evidence of febrile neutropenia.